טוען...
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia
Rapid development of the small molecule proteasome inhibitor bortezomib has yielded important clinical benefit for patients with multiple myeloma. Early phase clinical trials suggest the agent has similar efficacy in Waldenströms Macroglobulinemia. Optimization of bortezomib-based therapy, though, r...
שמור ב:
| Main Authors: | , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2009
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3133638/ https://ncbi.nlm.nih.gov/pubmed/19452315 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428190902866732 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|